Literature DB >> 19648253

Sphingosine 1-phosphate is an important endogenous cardioprotectant released by ischemic pre- and postconditioning.

Donald A Vessey1, Luyi Li, Norman Honbo, Joel S Karliner.   

Abstract

Exogenous sphingosine 1-phosphate (S1P) is an effective cardioprotectant against ischemic injury. We have investigated the hypothesis that S1P is also an important endogenous cardioprotectant released during both ischemic preconditioning (IPC) and ischemic postconditioning (IPOST). IPC of ex vivo rat hearts was instituted by two cycles of 3 min ischemia-5 min reperfusion prior to 40 min of index ischemia and then 40 min of reperfusion. IPC resulted in 70% recovery of left ventricular developed pressure (LVDP) upon reperfusion and a small infarct size (10%). VPC23019 (VPC), a specific antagonist of S1P(1 and 3) G protein-coupled receptors (GPCRs), when present during preconditioning blocked protection afforded by two cycles of IPC. VPC also blocked preconditioning of isolated rat cardiac myocytes subjected to hypoxia-reoxygenation injury. Increased release of S1P from myocytes in response to IPC was also demonstrated. These data indicate that S1P is released from myocytes in response to IPC and protects by binding to S1P GPCRs. In the ex vivo heart, if a third cycle of IPC was added to increase release of endogenous mediators, then the need for any individual mediator (e.g., S1P) was diminished and VPC had little effect. The adenosine antagonist 8-(p-sulfophenyl)-theophylline (8-SPT) likewise inhibited protection by two cycles but not three cycles of IPC, but VPC plus 8-SPT inhibited protection by three cycles of IPC. Similar to IPC, IPOST induced by four postindex ischemia cycles of 15 s reperfusion-15 s ischemia resulted in 66% recovery of LVDP and a 7% infarct size. When VPC was present during postconditioning and reperfusion, LVDP only recovered by 26% and the infarct size increased to 27%. Adding an additional cycle of IPOST reduced the inhibitory effect of VPC and 8-SPT individually, but not their combined effect. These studies reveal that S1P is an important mediator of both IPC and IPOST that is released along with adenosine during each cycle of IPC or IPOST.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19648253      PMCID: PMC2770755          DOI: 10.1152/ajpheart.00358.2009

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  30 in total

1.  Sphingosine 1-phosphate analogs as receptor antagonists.

Authors:  Michael D Davis; Jeremy J Clemens; Timothy L Macdonald; Kevin R Lynch
Journal:  J Biol Chem       Date:  2004-12-08       Impact factor: 5.157

2.  Cardioprotection mediated by sphingosine-1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts.

Authors:  Zhu-Qiu Jin; Hui-Zhong Zhou; Peili Zhu; Norman Honbo; Daria Mochly-Rosen; Robert O Messing; Edward J Goetzl; Joel S Karliner; Mary O Gray
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-06       Impact factor: 4.733

Review 3.  Myocardial reperfusion injury: experimental evidence and clinical relevance.

Authors:  P R Hansen
Journal:  Eur Heart J       Date:  1995-06       Impact factor: 29.983

4.  Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features.

Authors:  E Deutsch; M Berger; W G Kussmaul; J W Hirshfeld; H C Herrmann; W K Laskey
Journal:  Circulation       Date:  1990-12       Impact factor: 29.690

5.  The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes.

Authors:  J S Karliner; N Honbo; K Summers; M O Gray; E J Goetzl
Journal:  J Mol Cell Cardiol       Date:  2001-09       Impact factor: 5.000

6.  A rapid radioassay for sphingosine kinase.

Authors:  Donald A Vessey; M Kelley; Joel S Karliner
Journal:  Anal Biochem       Date:  2005-02-01       Impact factor: 3.365

7.  Signals from type 1 sphingosine 1-phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia.

Authors:  Jianqing Zhang; Norman Honbo; Edward J Goetzl; Kanu Chatterjee; Joel S Karliner; Mary O Gray
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-08-31       Impact factor: 4.733

8.  Ischemic Preconditioning And Myocardial Infarction: An Update and Perspective.

Authors:  Eric R Gross; Garrett J Gross
Journal:  Drug Discov Today Dis Mech       Date:  2007

9.  Combined sphingosine, S1P and ischemic postconditioning rescue the heart after protracted ischemia.

Authors:  Donald A Vessey; Luyi Li; Michael Kelley; Joel S Karliner
Journal:  Biochem Biophys Res Commun       Date:  2008-08-14       Impact factor: 3.575

Review 10.  Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury.

Authors:  Elizabeth Murphy; Charles Steenbergen
Journal:  Physiol Rev       Date:  2008-04       Impact factor: 37.312

View more
  41 in total

1.  Endogenous cardioprotection by ischaemic postconditioning and remote conditioning.

Authors:  Weiwei Shi; Jakob Vinten-Johansen
Journal:  Cardiovasc Res       Date:  2012-02-09       Impact factor: 10.787

Review 2.  Lysophospholipids in coronary artery and chronic ischemic heart disease.

Authors:  Ahmed Abdel-Latif; Paula M Heron; Andrew J Morris; Susan S Smyth
Journal:  Curr Opin Lipidol       Date:  2015-10       Impact factor: 4.776

3.  RhoA regulates Drp1 mediated mitochondrial fission through ROCK to protect cardiomyocytes.

Authors:  Cameron S Brand; Valerie P Tan; Joan Heller Brown; Shigeki Miyamoto
Journal:  Cell Signal       Date:  2018-06-25       Impact factor: 4.315

4.  Selective coupling of the S1P3 receptor subtype to S1P-mediated RhoA activation and cardioprotection.

Authors:  Bryan S Yung; Cameron S Brand; Sunny Y Xiang; Charles B B Gray; Christopher K Means; Hugh Rosen; Jerold Chun; Nicole H Purcell; Joan Heller Brown; Shigeki Miyamoto
Journal:  J Mol Cell Cardiol       Date:  2016-12-23       Impact factor: 5.000

5.  S1P receptor 1-Mediated Anti-Renin-Angiotensin System Cardioprotection: Pivotal Role of Mast Cell Aldehyde Dehydrogenase Type 2.

Authors:  Alice Marino; Takuya Sakamoto; Pablo A Robador; Kengo Tomita; Roberto Levi
Journal:  J Pharmacol Exp Ther       Date:  2017-05-12       Impact factor: 4.030

Review 6.  Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors.

Authors:  K Alexa Orr Gandy; Lina M Obeid
Journal:  Biochim Biophys Acta       Date:  2012-07-16

7.  Targeted focal adhesion kinase activation in cardiomyocytes protects the heart from ischemia/reperfusion injury.

Authors:  Zhaokang Cheng; Laura A DiMichele; Zeenat S Hakim; Mauricio Rojas; Christopher P Mack; Joan M Taylor
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03-01       Impact factor: 8.311

8.  The immunosuppressant FTY720 prolongs survival in a mouse model of diet-induced coronary atherosclerosis and myocardial infarction.

Authors:  Guanying Wang; Roy Y Kim; Isabella Imhof; Norman Honbo; Fu Sang Luk; Kang Li; Nikit Kumar; Bo-Qing Zhu; Delphine Eberlé; Daniel Ching; Joel S Karliner; Robert L Raffai
Journal:  J Cardiovasc Pharmacol       Date:  2014-02       Impact factor: 3.105

9.  IL-15: a novel prosurvival signaling pathway in cardiomyocytes.

Authors:  Yerem Yeghiazarians; Norman Honbo; Isabella Imhof; Brandon Woods; Vanessa Aguilera; Jianqin Ye; Andrew J Boyle; Joel S Karliner
Journal:  J Cardiovasc Pharmacol       Date:  2014-05       Impact factor: 3.105

Review 10.  Cardioprotection in ischemia/reperfusion injury: spotlight on sphingosine-1-phosphate and bradykinin signalling.

Authors:  Emmanuel Eroume A Egom; Yunbo Ke; R John Solaro; Ming Lei
Journal:  Prog Biophys Mol Biol       Date:  2010-01-18       Impact factor: 3.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.